General Information of Drug (ID: DM8104I)

Drug Name
RG6512 Drug Info
Indication
Disease Entry ICD 11 Status REF
Haemophilia A 3B10.0 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DM8104I

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug(s) Targeting Coagulation factor IX (F9)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Emicizumab DM0AQ83 Factor VIII deficiency 3B10 Approved [2]
Recombinant Factor IX DMY7ESM Bleeding disorder GA20-GA21 Approved [3]
CSL-654 DMZJGVL Factor IX deficiency 3B11 Phase 3 [4]
RG6013 DMER75Y Haemophilia A 3B10.0 Phase 3 [5]
AMT-061 DMSO02K Haemophilia B 3B11.0 Phase 3 [6]
Fidanacogene elaparvovec DMFZ81T Haemophilia B 3B11.0 Phase 3 [7]
Mim8 DMX33ZR Haemophilia A 3B10.0 Phase 3 [8]
TTP889 DMCQARM Blood forming organ disorder JB64.1 Phase 2 [9]
AMT-060 DM7RNKM Factor IX deficiency 3B11 Phase 1/2 [10]
SB-FIX DMUP52Y Haemophilia B 3B11.0 Phase 1/2 [11]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Coagulation factor Xa (F10)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Apixaban DM89JLN Thrombosis DB61-GB90 Approved [12]
Rivaroxaban DMQMBZ1 Deep vein thrombosis BD71 Approved [13]
DU-176b DMCIJBH Atrial fibrillation BC81.3 Approved [14]
Emicizumab DM0AQ83 Factor VIII deficiency 3B10 Approved [2]
BETRIXABAN DM2C4RF Venous thromboembolism BD72 Approved [15]
Lmw heparin DMJPD06 Coagulation defect 3B10.0 Approved [16]
Nadroparin calcium DMBNKST Coagulation defect 3B10.0 Approved [17]
Fondaparinux sodium DMWS3FH Deep vein thrombosis BD71 Approved [18]
Danaparoid DM6CLBN Deep venous clot BD71 Approved [19]
Coagulation Factor IX DM8HBJI Haemophilia B 3B11.0 Approved [20]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Coagulation factor IX (F9) TTFEZ5Q FA9_HUMAN Not Available [1]
Coagulation factor Xa (F10) TTCIHJA FA10_HUMAN Not Available [1]

References

1 Clinical pipeline report, company report or official report of Roche
2 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
3 BAX326 (RIXUBIS): a novel recombinant factor IX for the control and prevention of bleeding episodes in adults and children with hemophilia B. Ther Adv Hematol. 2014 Oct;5(5):168-80.
4 Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. Blood. 2012 September 20; 120(12): 2405-2411.
5 Anti-factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation. J Thromb Haemost. 2014 Feb;12(2):206-13.
6 Clinical pipeline report, company report or official report of uniQure.
7 Factor IX assay discrepancies in the setting of liver gene therapy using a hyperfunctional variant factor IX-Padua. J Thromb Haemost. 2021 May;19(5):1212-1218.
8 ClinicalTrials.gov (NCT05878938) Open-label Safety Study in Adults and Adolescents With Haemophilia A With and Without FVIII Inhibitors Switching Directly From Emicizumab Prophylaxis to NNC0365-3769 (Mim8) Prophylaxis. U.S.National Institutes of Health.
9 Partial factor IXa inhibition with TTP889 for prevention of venous thromboembolism: an exploratory study. J Thromb Haemost. 2008 Mar;6(3):457-63.
10 Phase I/II clinical trial of AMT-060 for treating hemophilia B. uniQure N.V.
11 ClinicalTrials.gov (NCT02695160) Ascending Dose Study of Genome Editing by Zinc Finger Nuclease Therapeutic SB-FIX in Subjects With Severe Hemophilia B. U.S. National Institutes of Health.
12 Pfizer. Product Development Pipeline. March 31 2009.
13 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
14 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2359).
15 Company report (Portola)
16 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
17 Serum zinc concentrations: contamination from laboratory equipment. JPEN J Parenter Enteral Nutr. 1979 May-Jun;3(3):179-81.
18 Biochemistry and clinical pharmacology of new anticoagulant agents. Pathophysiol Haemost Thromb. 2002 Sep-Dec;32(5-6):218-24.
19 Effect of factor X inhibition on coagulation activation and cytokine induction in human systemic inflammation. J Infect Dis. 2002 Nov 1;186(9):1270-6.
20 Haemophilia B: Christmas disease. Expert Opin Pharmacother. 2005 Aug;6(9):1517-24.